Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX:PBT) covers the period ending June 1, 2015. The registrant is a foreign private issuer based in Australia. The filing primarily discloses a change in the director's interest in securities pursuant to ASX Listing Rule 3.19A.2 and Section 205G of the Corporations Act.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director shareholdings and does not contain financial statements or performance metrics.
Material Changes
The material change disclosed is an increase in the indirect shareholding of Executive Chairman Mr. Geoffrey Kempler.
- Transaction Type: On-market acquisition.
- Securities Acquired: 200,000 Ordinary Shares (Indirect interest).
- Consideration: $50,550.
- Post-Transaction Holdings: Total of 18,011,000 Ordinary Shares (30,000 Direct, 17,981,000 Indirect) and 4,000,000 Options (Direct).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a notice of change in director interest.
Investor Verification Checklist
- Verify the current market price of Prana Biotechnology Limited shares to confirm the valuation of the $50,550 acquisition.
- Confirm the total outstanding share capital to assess the percentage ownership represented by the 18,011,000 shares held by the Executive Chairman.
- Review the terms and expiry dates of the 4,000,000 options held directly by the Executive Chairman.
- Check for any subsequent filings regarding further changes in director interests or closed period trading restrictions.